ZOLETIL 100 (50 mg/ml + 50 mg/ml) LIOFILIZADO Y DISOLVENTE PARA SOLUCION INYECTABLE
ZOLETIL 100 (50 mg/ml + 50 mg/ml) LIOFILIZADO Y DISOLVENTE PARA SOLUCION INYECTABLE
Authorised
- Zolazepam hydrochloride
- Tiletamine hydrochloride
Product identification
Medicine name:
ZOLETIL 100 (50 mg/ml + 50 mg/ml) LIOFILIZADO Y DISOLVENTE PARA SOLUCION INYECTABLE
Active substance:
- Zolazepam hydrochloride
- Tiletamine hydrochloride
Target species:
-
Dog
-
Cat
Route of administration:
-
Intravenous use
-
Intramuscular use
Product details
Active substance and strength:
-
Zolazepam hydrochloride250.00/milligram(s)5.00millilitre(s)
-
Tiletamine hydrochloride250.00/milligram(s)5.00millilitre(s)
Pharmaceutical form:
-
Powder and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QN01AX99
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Spain
Package description:
- Available only in Spanish
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Virbac Espana S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
- Virbac
Responsible authority:
- Spanish Agency Of Medicines And Medical Devices
Authorisation number:
- 2570 ESP
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Spanish (PDF)
Published on: 30/10/2025
Labelling
This document does not exist in this language (English). You can find it
in another language below.
Spanish (PDF)
Published on: 30/10/2025
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Spanish (PDF)
Published on: 30/10/2025